CoChat

Reexamining Metrics for Glucose Control

Rubinow, Katya B. · 2011 · JAMA
Cited by 39

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

THE HEMOGLOBIN A1C (HBA1C) ASSAY WAS FIRST USED more than 30 years ago as a marker of diabetes control. Despite its availability for 2 decades, HbA1c testing did not assume a central role in diabetes care until the publication of 2 major clinical trials. The Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) demonstrated that HbA1c level strongly predicts risk of microvascular complications associated with type 1 and type 2 diabetes, respectively. Largely consequent to these findings, HbA1c level has become the primary basis for diabetes diagnosis, treatment decisions, and assessment of quality health care. As clinical application of HbA1c measurement expands, so does the need for caution in its interpretation and appreciation of its substantial limitations. The unreliability of HbA1c findings has been recognized in a number of clinical settings. Among the most frequently cited are hematologic conditions, including anemia, hemolysis, variable red blood cell life span, reticulocytosis, and hemoglobinopathies. A variety of less appreciated clinical factors can affect the concordance of HbA1c level with mean blood glucose (MBG) level. These include the use of certain medications (dapsone, erythropoietin), mechanical heart valves, and hypothyroidism. Differential glycation rates also can produce variability in HbA1c values, and rates of protein glycation appear to vary to a much greater extent across individuals than historically has been appreciated. When HbA1c values are compared systematically with MBG values generated by continued glucose monitoring, the range of corresponding MBG for an HbA1c of 8% spans 70 mg/dL; this variability increases even further at higher HbA1c values and may derive substantially from heterogeneity in glycation rates. In a pediatric population of patients with type 1 diabetes, roughly equivalent MBG values corresponded to an HbA1c level of 7.6% among “low glycators” and 9.6% among “high glycators.” These data derive from a study population that simply was divided into tertiles on the basis of differential glycation. Further, differential glycation appears not only a source of HbA1c measurement variability but possibly an independent predictor of diabetes-related microvascular complications. Cohen et al reported that the glycation gap—the difference between glycated fructosamine and glycated hemoglobin—is associated with risk of incident retinopathy in a diabetic population. Differential glycation may have a substantial hereditary basis. The hemoglobin glycation index also has been proposed as an independent predictor of microvascular complications, although this has been refuted on the basis of the strong correlation between HbA1c values and the hemoglobin glycation index. More recently, greater recognition has evolved of the effects of race on HbA1c level, with particular focus on the implications for new diagnosis of diabetes. For comparable MBG values, HbA1c values vary by 0.2% to 0.65% across racial backgrounds. These findings suggest that an HbA1c level of 6.5% may be too sensitive a threshold for diagnosis in some populations and an inadequate threshold in others. The DCCT did not address the possibility that risk of microvascular complications may be conferred at variant HbA1c values across race; it included only patients with type 1 diabetes, a racially homogeneous population. This racial bias was skewed further by the exclusion of study participants with an abnormal hemoglobin electrophoresis and calls into question the fundamental applicability of the DCCT findings to nonwhite patients. The UKPDS similarly lacked racial heterogeneity, as 81% of study participants were white, whereas only 10% were Asian and 8% African Caribbean. The continual identification of sources of variability in HbA1c level has generated interest in the use of alternative, integrative measures of MBG. Expanded use of either fructosamine or glycated albumin, for example, has been advocated for the diagnosis of diabetes and treatment monitoring. Fructosamine offers the advantage of gauging shorterterm glycemic control; however, fructosamine does not correlate strongly with fasting plasma glucose and is a rela-

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2011.314

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 39

Metadata

Authors
Rubinow, K. B.
Venue
JAMA
Published
2011-03-16
Volume
305
Issue
11
Pages
1132
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W1978331227
Cited by
39
References
2
FWCI
4.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reexamining Metrics for Glucose Control. https://app.cochat.ai/papers/10.1001/jama.2011.314
The paper
Rubinow, K. B. (2011). Reexamining Metrics for Glucose Control. JAMA. https://doi.org/10.1001/jama.2011.314

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.